Pulsed Electromagnetic Fields Protect Against Brain Ischemia by Modulating the Astrocytic Cholinergic Anti-inflammatory Pathway

Zhang, Haofuzi; Yang, Yuefan; Yang, Erwan; Tian, Zhicheng; Huang, Yutao; Zhang, Zhuoyuan; Bao, Mingdong; Liao, Dan; Ge, Junmiao; Wang, Chao; Li, Xin; Luo, Peng

doi:10.1007/s10571-022-01251-2

Cited by 3 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary astrocytes were prepared as previously described . To generate a cell suspension, the brain was chopped and trypsinized.…”

Section: Methodsmentioning

confidence: 99%

“…Primary astrocytes were prepared as previously described. 68 To generate a cell suspension, the brain was chopped and trypsinized. The collected cells were suspended in DMEM (Gibco, CA) supplemented with 10% FBS and cultured in T75 bottles coated with poly- l -lysine (Sigma–Aldrich, St. Louis, MO, USA) at 37 °C in a humid atmosphere with 5% CO 2 .…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Observing Extracellular Vesicles Originating from Endothelial Cells in Vivo Demonstrates Improved Astrocyte Function Following Ischemic Stroke via Aggregation-Induced Emission Luminogens

et al. 2023

Self Cite

View full text Add to dashboard Cite

Extracellular vesicles (EVs) obtained from endothelial cells (ECs) have significant therapeutic potential in the clinical management of individuals with ischemic stroke (IS) because they effectively treat ischemic stroke in animal models. However, because molecular probes with both high labeling efficiency and tracer stability are lacking, monitoring the actions of EC-EVs in the brain remains difficult. The specific intracellular targets in the brain that EC-EVs act on to produce their protective effects are still unknown, greatly impeding their use in clinical settings. For this research, we created a probe that possessed aggregation-induced emission (AIE) traits (namely, TTCP), enabling the effective labeling of EC-EVs while preserving their physiological properties. In vitro, TTCP simultaneously had a higher EC-EV labeling efficiency and better tracer stability than the commercial EV tags PKH-67 and DiI. In vivo, TTCP precisely tracked the actions of EC-EVs in a mouse IS model without influencing their protective effects. Furthermore, through the utilization of TTCP, it was determined that astrocytes were the specific cells affected by EC-EVs and that EC-EVs exhibited a safeguarding impact on astrocytes following cerebral ischemia-reperfusion (I/R) injury. These protective effects encompassed the reduction of the inflammatory reaction and apoptosis as well as the enhancement of cell proliferation. Further analysis showed that miRNA-155-5p carried by EC-EVs is responsible for these protective effects via regulation of the c-Fos/AP-1 pathway; this information provided a strategy for IS therapy. In conclusion, TTCP has a high EC-EV labeling efficiency and favorable in vivo tracer stability during IS therapy. Moreover, EC-EVs are absorbed by astrocytes during cerebral I/R injury and promote the restoration of neurological function through the regulation of the c-Fos/AP-1 signaling pathway.

show abstract

“…Primary astrocytes were prepared as previously described . To generate a cell suspension, the brain was chopped and trypsinized.…”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%